Business
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update
- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 -- Topline Phase 2 CBP-307 Results in
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 -- Topline Phase 2 CBP-307 Results in Moderate-to-Severe Ulcerative Colitis Expected to Be Reported in H1 2022 -- Cash Balance of RMB 1,706.9 million (USD 267.7 million) at December 31, 2021 - SAN DIEGO, CA and TAICANG, SUZHOU, China, March 31, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global, clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell-driven research, today announced financial results for the full year ended December 31, 2021 and recent corporate highlights. “During the past year, we advanced the clinical development of our lead assets CBP-201 and CBP-307, each having potentially differentiated product profiles for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and ulcerative colitis, diseases with large patient populations with significant unmet need,” said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma. “Our data from the global Phase 2b trial of CBP-201 in patients with atopic dermatitis gives us confidence in the potential that CBP-201 could have a highly competitive efficacy and safety profile with low incidence of conjunctivitis, and the convenience of dosing every four weeks. In the coming 12 months, we have a number of key milestones anticipated for CBP-201, including initiating our global Phase 3 program in atopic dermatitis and completing enrollment in both our pivotal trial in atopic dermatitis in China, and in our Phase 2 trial in asthma. We also look forward to reporting topline results from our Phase 2 trial of CBP-307 in patients with moderate-to-severe ulcerative colitis in the first half of 2022.” Second Half 2021 and Recent Operating Highlights Reported positive data from global Phase 2b trial of CBP-201 in moderate-to-severe atopic dermatitis (AD): In January 2022, the Company reported detailed positive data from the global Phase 2b clinical trial of CBP-201 administered subcutaneously to adult patients with moderate-to-severe AD. CBP-201 met all primary and key secondary efficacy endpoints, with favorable safety data reporting low incidences of injection site reactions, conju...